Vaccine最新文献

{"title":"Evidence on trends in uptake of childhood vaccines and association with COVID-19 vaccination rates.","authors":"Ali Moghtaderi, Timothy Callaghan, Qian Luo, Matt Motta, Tina Q Tan, Laura Hillard, Avi Dor, Allison Portnoy, Amy Winter, Bernard Black","doi":"10.1016/j.vaccine.2024.126631","DOIUrl":"https://doi.org/10.1016/j.vaccine.2024.126631","url":null,"abstract":"<p><strong>Importance: </strong>Childhood vaccination rates have declined in recent years; there is also concern that resistance to COVID-19 vaccines could spill over to childhood vaccines.</p><p><strong>Objectives: </strong>To use local-level data to study trends in childhood vaccination rates and heterogeneity in local rates; including how many areas are below herd-immunity thresholds, and assess the association between COVID-19 vaccine hesitancy and childhood vaccination.</p><p><strong>Design: </strong>We report, for 11 states with available data, vaccination rates for measles, mumps, rubella (MMR), and diphtheria, tetanus, acellular pertussis (DTaP) vaccines, including percentage of schools/counties with rates ≥95 %, 90-95 %, 80-90 %, and < 80 %. We also study the association between county-level COVID-19 vaccination rates and change from 2019 to 2022 in MMR and DTaP vaccination rates.</p><p><strong>Exposure: </strong>School/county level vaccination rates; county-level COVID-19 vaccine hesitancy, proxied by the percent of the adult population in each county that did not complete primary COVID-19 vaccination.</p><p><strong>Main outcomes: </strong>Percentage of school/counties with MMR/DTaP vaccination rates within specified ranges, mean vaccination rates, and change in MMR/DTaP vaccination rates between 2019 and 2022.</p><p><strong>Results: </strong>On average, childhood vaccination rates declined from 2019 to 2022 in states that allow non-medical exemptions, but with substantial heterogeneity within and across states. The largest declines were in already low-vaccination schools. COVID-19 vaccine hesitancy was associated with a somewhat larger 2019-to-2022 decline in childhood vaccination rates in rural counties and strongly Republican-leaning counties.</p><p><strong>Conclusion: </strong>Vaccination rates fell from 2019 to 2022, continuing a longer trend toward lower rates. For measles and pertussis, childhood vaccination rates are below herd-immunity levels in many local communities, sometimes substantially so. We used two proxies for potential spillover of COVID-19 vaccine hesitancy to childhood vaccines (rural indicator and Republican-leaning indicator); these proxies can explain a modest part of the decline childhood vaccination in rural and Republican-leaning counties, but most of the explanation lies elsewhere.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":"45 ","pages":"126631"},"PeriodicalIF":0.0,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142866951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Staff and caregivers' perceptions of digital storytelling to increase influenza vaccine confidence in an urban safety-net healthcare system.","authors":"Joshua T B Williams, Carly Ritger, Brooke Dorsey Holliman, Amy G Huebschmann, Sean T O'Leary","doi":"10.1016/j.vaccine.2024.126572","DOIUrl":"https://doi.org/10.1016/j.vaccine.2024.126572","url":null,"abstract":"<p><strong>Background: </strong>Myriad risk factors contribute to pediatric influenza vaccination disparities. Digital stories are compelling accounts of lived experience that have been useful in health promotion, especially in minoritized communities. Little is known about how they are perceived as a behavioral intervention to improve influenza vaccination confidence in safety-net healthcare systems.</p><p><strong>Objective: </strong>To explore staff and caregivers' perceptions of Digital Storytelling (DST) as a behavioral intervention to improve influenza vaccine confidence among caregivers of children.</p><p><strong>Methods: </strong>This qualitative study was set in two federally qualified health centers in historically Black neighborhoods in Denver, Colorado, USA. Informal group discussions with clinic staff probed perceptions of vaccine disparities, clinic priorities, and DST. Individual interviews with key staff and caregivers of children 6 months to 5 years old explored perceptions of and preferences for DST to improve vaccine confidence. Interviews were recorded and transcribed verbatim. Three researchers analyzed transcripts via directed content analysis using a deductive approach based off the IM4Equity framework. Final themes were member-checked with clinic staff, pediatric providers, and community advisors.</p><p><strong>Results: </strong>Approximately 70 staff attended informal group discussions; 13 staff and 12 caregivers participated in key informant interviews. Transcripts from group discussions (n = 6) and individual interviews (n = 23) were included in final analyses. Staff felt existing influenza vaccination strategies were inadequate, perceived digital stories meaningfully, and desired equitable implementation without responsibility for implementing them. Caregivers perceived DST as compelling, noted the importance of trusted storytellers, and suggested relatable stories from diverse caregivers could be sent via text messages in the winter to cue caregivers to action.</p><p><strong>Conclusions: </strong>In this qualitative study, staff and caregivers perceived DST favorably, with preferences specific to DST implementation in a large, diverse health system. Work to develop and implement text-based DST for pediatric influenza vaccination in this context is warranted.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":"45 ","pages":"126572"},"PeriodicalIF":0.0,"publicationDate":"2024-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142840674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictors of severity of SARS-CoV-2 infections in Brazil: Post hoc analyses of a randomised controlled trial.","authors":"Kerry Conlin, Daniel Jenkin, Philip de Whalley, Lily Yin Weckx, Pedro M Folegatti, Sagida Bibi, Teresa Lambe, Parvinder K Aley, Andrew J Pollard, Merryn Voysey, Sue Ann Costa Clemens","doi":"10.1016/j.vaccine.2024.126582","DOIUrl":"https://doi.org/10.1016/j.vaccine.2024.126582","url":null,"abstract":"<p><strong>Objectives: </strong>To identify demographic, clinical and immunological factors associated with adverse COVID-19 outcomes.</p><p><strong>Methods: </strong>A large randomised controlled trial of ChAdOx1 nCoV-19 was undertaken in Brazil. Participants were randomised 1:1 either to receive ChAdOx1 nCov-19 or to a control group. COVID-19 infections were confirmed by nucleic acid amplification test (NAAT) and classified using the WHO clinical progression scale. Anti-spike antibody responses and serum neutralising activity were measured 28 days after second vaccination in some participants. Exploratory analyses were conducted into factors associated with COVID-19 infection severity and hospitalisation, using logistic regression models adjusted for demographic and clinical factors.</p><p><strong>Results: </strong>10,416 participants were enrolled; 1790 had NAAT-positive COVID-19 infection; 63 cases required hospitalisation. More severe infection was associated with greater body-mass index (BMI) (odds ratio [OR] = 1.06 [95 %CI: 1.01-1.10], p = 0.01) and diabetes (OR = 3.67 [1.59-8.07], p = 0.003). Hospitalisation risk increased with greater age (OR = 1.06 [1.03-1.08], p < 0.001) and BMI (OR = 1.10 [1.05-1.16], p < 0.001). More severe infection and hospitalisation risks increased >180 days after last vaccination. In the fully vaccinated subgroup (n = 841), only greater age predicted hospitalisation (OR = 1.07 [1.03-1.12], p < 0.001). Serological responses to two vaccine doses diminished with age.</p><p><strong>Conclusions: </strong>Unvaccinated individuals with high BMI and diabetes risked more severe COVID-19 outcomes. Vaccination mitigated this risk.</p><p><strong>Clinical trial registration number: </strong>NCT04536051.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":"45 ","pages":"126582"},"PeriodicalIF":0.0,"publicationDate":"2024-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142831406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changes in population genetic structure of serotype 19A Streptococcus pneumoniae after universal childhood use of the 10-valent pneumococcal conjugate vaccine in Brazil.","authors":"Jailton L C Lima, Amanda B da Silva, Amanda S Cabral, Filipe M de Miranda, Lívia D da Silva, André R A da Silva, Lúcia M Teixeira, Felipe P G Neves","doi":"10.1016/j.vaccine.2024.126588","DOIUrl":"https://doi.org/10.1016/j.vaccine.2024.126588","url":null,"abstract":"<p><strong>Background: </strong>The introduction of the 10-valent pneumococcal conjugate vaccine (PCV10) for nationwide childhood immunization in 2010 led to a significant reduction in colonization and invasive pneumococcal disease (IPD) by vaccine serotypes in young. However, non-vaccine serotypes have emerged, and serotype 19A is now the leading cause of IPD in Brazil.</p><p><strong>Methods: </strong>We analyzed 32 serotype 19A isolates of Streptococcus pneumoniae recovered from children and adults who attended different health facilities in the state of Rio de Janeiro, Brazil, between 2010 and 2023. The capsular types of the isolates were determined by sequential multiplex PCR or by cpsB gene sequencing. All isolates were subjected to antimicrobial susceptibility testing and MLST.</p><p><strong>Results: </strong>Of the 32 serotype 19A isolates, 29 (90.6 %) isolates were recovered from children aged ≤5 years and three (9.4 %) isolates were recovered from adults. Nineteen (59.4 %) isolates were associated with colonization, and 13 (40.6 %) isolates were from diseases. All isolates were susceptible to chloramphenicol, levofloxacin, linezolid, rifampin, and vancomycin. The highest frequencies of non-susceptibility (intermediate + resistant) were observed for sulfamethoxazole-trimethoprim (n = 30; 93.8 %), penicillin (n = 24; 75 %), and erythromycin (n = 23; 71.9 %). Twenty-two (68.8 %) isolates were multidrug resistant (MDR). MICs for penicillin among penicillin-non-susceptible pneumococci (PNSP) ranged from 0.12 to 8.0 μg/mL. MICs for erythromycin ranged from 0.064 to >256 μg/mL. MICs for ceftriaxone ranged from 0.023 to 4 μg/mL. The most common genetic lineages were ST733 (n = 7; 21.9 %), mostly found before and in the early years of PCV10 introduction, and CC320 (n = 25; 78.1 %), mostly found in the late-PCV10 period. All 25 isolates within CC320 were PNSP and mostly (n = 22; 88 %) MDR.</p><p><strong>Conclusions: </strong>We observed a shift in antimicrobial susceptibility profiles and genetic lineages after long-term use of PCV, mostly PCV10, for routine childhood immunization, characterized by clonal expansion of the MDR lineage CC320.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":"45 ","pages":"126588"},"PeriodicalIF":0.0,"publicationDate":"2024-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142831455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Everyone, everywhere, all the time: Ten lessons yet to be learned from the SARS-CoV-2 pandemic.","authors":"Gregory A Poland","doi":"10.1016/j.vaccine.2024.126590","DOIUrl":"https://doi.org/10.1016/j.vaccine.2024.126590","url":null,"abstract":"","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":"45 ","pages":"126590"},"PeriodicalIF":0.0,"publicationDate":"2024-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142831403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Field vaccination of locally-owned cattle against malignant catarrhal fever under environmentally challenging conditions in Tanzania.","authors":"Samuel Bainbridge, Tauta Mappi, Sarah Cleaveland, Choby Chubwa, Alicia Davis, Dawn Grant, Tito Kibona, Shedrack Bwatota, Freja Larsen, Samson Lyimo, Fadhili Mshana, Ann Percival, Gabriel Shirima, Bakari Mtili, Felix Jackson Musyangi, Rigobert Tarimo, Felix Lankester, George Russell","doi":"10.1016/j.vaccine.2024.126587","DOIUrl":"https://doi.org/10.1016/j.vaccine.2024.126587","url":null,"abstract":"<p><p>Malignant catarrhal fever (MCF), caused by alcelaphine herpesvirus-1 (AIHV-1) transmitted from wildebeest, is a lethal cattle disease with significant impacts on East African pastoralists. Development of a live attenuated MCF vaccine has prompted research into its use in communities at risk. This study reports results from the first utilisation of the MCF vaccine in locally-owned cattle under field conditions. The study involved a primary two-dose course vaccination of 1634 cattle, followed a year later, by boost vaccination of 385 of these cattle. It aimed to: (a) evaluate the antibody response to a two-dose AlHV-1 primary vaccination course, including initial response, antibody levels after one year, and clinical events post-vaccination; (b) assess how factors like age, reproductive status, body condition, and breed influence the initial response; and (c) compare antibody responses to single- and two-dose booster protocols one year after primary vaccination. Analyses were carried out using linear mixed-effects models and paired t-tests. Clinical incidents were reported in 11/1634 cattle vaccinated during the primary course and in 0/385 cattle during the boost regimens. The primary vaccination resulted in a 9-fold increase in comparison to pre-vaccination antibody levels and the response was consistent across animals of different ages, reproductive statuses and body conditions. While antibody levels declined 11 months after primary vaccination, they remained high, and a single-dose booster vaccination was sufficient to elicit a strong immune response, with only marginal increases after a second booster. The study provides evidence of high immunogenicity and low incidences of clinical events of the vaccine in cattle across individual host factors and immunologically vulnerable groups, under prevailing environmental conditions. It also indicates the utility of a single-dose booster regimen. These findings will support progress towards commercial production and larger-scale adoption which could generate important benefits for the livelihoods, and sustainability of pastoral livestock systems.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":"45 ","pages":"126587"},"PeriodicalIF":0.0,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142824996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mental illness and antibody responses after COVID-19 vaccination in a prospective population-based study in Catalonia.","authors":"Marianna Karachaliou, Ana Espinosa, Xavier Farré, Natalia Blay, Gemma Castaño-Vinyals, Susana Iraola-Guzmán, Rocio Rubio, Marta Vidal, Alfons Jiménez, Marc Bañuls, Ruth Aguilar, Judith Garcia-Aymerich, Carlota Dobaño, Manolis Kogevinas, Gemma Moncunill, Rafael de Cid","doi":"10.1016/j.vaccine.2024.126591","DOIUrl":"https://doi.org/10.1016/j.vaccine.2024.126591","url":null,"abstract":"<p><p>Background Mental illnesses have been overlooked as a potential factor influencing antibody responses to COVID-19 vaccine. Associations between mental disorders and antibody response might vary by specific disorders, depend on the long-term course of the illness and relate to psychotropic treatment.</p><p><strong>Methods: </strong>The association between mental illness diagnoses (mood affective disorders, anxiety disorders, other) over ten years and psychotropic drug prescription based on electronic health records with antibody levels (IgG and IgA) post COVID-19 vaccination was assessed in 939 vaccinated adults from Catalonia, Spain. We employed linear regression models to assess associations between specific mental illnesses and psychotropic drugs with antibody levels, correcting for demographics, comorbidities and lifestyle factors. In a genotyped subset (n = 247) we assessed the effect of polygenic risk scores (PRS) for mental illnesses and performed a two-sample mendelian randomization (MR) analysis to examine causality between mental illness and antibody responses.</p><p><strong>Results: </strong>Mood affective disorders were associated with lower IgG to receptor binding domain (RBD) [percentage change = -26.37 (95 % CI, -42.00, -6.54)]. Diagnosis of anxiety disorders was not associated with the outcome. The group of other diagnoses (mainly including insomnia and nicotine dependence) were associated with lower IgG RBD levels [percentage change: -21.53 (95 % CI, -35.38, -4.71)] and recent onset cases (≤5 years ago) showed greater decline in antibody levels. Participants on second-generation antipsychotics and multiple classes of psychotropic drugs in the last 6 months exhibited lower antibody levels. In the genotyped population, higher genetic liability (higher PRS) to schizophrenia was associated with lower IgG RBD levels [percentage change = -35.49 (95 % CI, -56.55, -4.23)]. MR analysis revealed a causal relationship between major depression genetic instrumental variables and lower IgG RBD and S levels.</p><p><strong>Conclusions: </strong>These findings raise concerns about the efficacy of COVID-19 vaccines and potentially of other vaccines as well, in individuals with mood affective disorders, current/recent insomnia and nicotine dependence and people on multiple psychotropic drugs. Whether these associations are translated into increased risk for breakthrough infections and immune mediated long-term sequels of the SARS-CoV-2 infection warrants further investigation.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":"45 ","pages":"126591"},"PeriodicalIF":0.0,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142823024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A single immunization with intranasal Newcastle disease virus (NDV)-based XBB.1.5 variant vaccine reduces disease and transmission in animals against matched-variant challenge.","authors":"Stefan Slamanig, Nicholas Lemus, Tsoi Ying Lai, Gagandeep Singh, Mitali Mishra, Adam Abdeljawad, Marta Boza, Victoria Dolange, Gagandeep Singh, Benhur Lee, Irene González-Domínguez, Michael Schotsaert, Florian Krammer, Peter Palese, Weina Sun","doi":"10.1016/j.vaccine.2024.126586","DOIUrl":"https://doi.org/10.1016/j.vaccine.2024.126586","url":null,"abstract":"<p><p>The rapid development of coronavirus disease 2019 (COVID-19) vaccines has helped mitigate the initial impact of the pandemic. However, in order to reduce transmission rates and protect more vulnerable and immunocompromised individuals unable to mount an effective immune response, development of a next-generation of mucosal vaccines is necessary. Here, we developed an intranasal Newcastle disease virus (NDV)-based vaccine expressing the spike of the XBB.1.5 variant stabilized in its pre-fusion conformation (NDV-HXP-S). We demonstrated that one or two intranasal immunizations with live NDV-HXP-S expressing the XBB.1.5 spike induces systemic and mucosal antibody responses in mice and protects them from a challenge with the XBB.1.5 variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Furthermore, one or two intranasal vaccinations with NDV-HXP-S XBB.1.5 protected hamsters from variant matched infection and reduced virus emission, thereby providing complete protection to naïve animals in a direct contact transmission study. The data shown in this study supports the notion that intranasal vaccination with variant-adapted NDV-HXP-S induces protective mucosal immunity and reduces transmission rates, highlighting the robust protective efficacy of a single mucosal vaccination in mice and hamsters.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":"45 ","pages":"126586"},"PeriodicalIF":0.0,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142820439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Seroconversion following PPSV23 vaccination in children with type 1 diabetes mellitus.","authors":"Elizabeth Ender, Avni Joshi, Melissa Snyder, Seema Kumar, Roland Hentz, Ana Creo","doi":"10.1016/j.vaccine.2024.126592","DOIUrl":"https://doi.org/10.1016/j.vaccine.2024.126592","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate whether children with type 1 diabetes mellitus (T1DM) have optimal humoral immune response to pneumococcal polysaccharide vaccination (PPSV23) and to study factors affecting that response.</p><p><strong>Methods: </strong>In this prospective pilot study, we recruited 29 children with T1DM who were vaccine naïve to PPSV23 and assessed serum-serotype specific IgG at baseline and 4-6 weeks post-immunization. We tested association between independent variables (age, gender, body mass index (BMI), hemoglobin A1c (HbA1c), glucose variability, and time in range assessed by continuous glucose monitors (CGM), insulin dose and outcome (log-2-fold change of immunoassay response between pre- and post-immunization testing) using linear regression.</p><p><strong>Results: </strong>Eighty-eight percent of children (22/25) who completed the study had overall appropriate response with a median 4.2-fold change following immunization. When assessing PPSV23-exclusive serotypes, there was a statistically significant correlation between increasing age and greater response (0.16 log2-fold change per year, 95 % CI (0.014 to 0.3), p = 0.033). Higher BMI for age (p = 0.085) and a lower coefficient of glucose variation from CGM following immunization (p = 0.067) also coincided with greater vaccine response, with correlation statistically significant for certain pneumococcal serotypes for both.</p><p><strong>Conclusions: </strong>Response to pneumococcal vaccination has not previously been assessed in children with T1DM, and our study demonstrates robust humoral immune response to PPSV23 vaccination in these children. Larger studies with a diverse representation and longer follow up to assess how humoral seroconversion correlates with clinical response to PPSV23 in this vulnerable population are warranted.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":"45 ","pages":"126592"},"PeriodicalIF":0.0,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142820486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the ethics of using fictional stories for health education on social media to share information and emotions about the HPV vaccine: A cross-sectional study with interdisciplinary health experts.","authors":"Philip M Massey, Regan M Murray, Kelli Kostizak, Wen-Juo Lo, Michael Yudell","doi":"10.1016/j.vaccine.2024.126575","DOIUrl":"https://doi.org/10.1016/j.vaccine.2024.126575","url":null,"abstract":"<p><p>Social media is used to promote the HPV vaccine through various strategies, including the use of stories and narratives. Understanding the ethical concerns related to the use of social media in this capacity are important. The purpose of this study is to identify ethical concerns of using fictional stories to share information and emotions about the HPV vaccine on social media, ultimately to influence parents on their decision to vaccinate their child.</p><p><strong>Methods: </strong>We conducted a cross-sectional survey with researchers in the fields of health communication, cancer prevention, social media, and public health ethics from October to December 2021. Respondents were presented with a fictional story that consisted of seven connected vignettes about the HPV vaccine. For each vignette, respondents were asked to rate the potential benefits and risk, as well as the potential for ethical concerns of using the fictional narrative style to share information about the HPV vaccine. Descriptive statistics summarized responses, and qualitative data were analyzed thematically.</p><p><strong>Results: </strong>On average, respondents (n = 41) perceived more benefits than risks when it comes to 1) using social media for health education generally and 2) using a story with connected vignettes for vaccine communication. The vignettes prioritizing vaccine hesitancy, positive emotion, and health equity were seen as having the most potential benefit, while the vignettes highlighting vaccine confidence and skepticism were seen as having the most potential risk. Overall, respondents felt there were several ethical concerns of note - persuasion was the most common (15 % of respondents) followed by deception (9 %) and manipulation (8 %). Qualitative data highlighted the importance of transparency and trust to avoid ethical violations and negative outcomes.</p><p><strong>Conclusions: </strong>Ethical concerns exist when using fictional stories to share health information on social media, particularly as new online technologies make it harder to tell fact from fiction. Practical and actionable recommendations for researchers must be developed, defining a range of ethical responsibilities.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":" ","pages":"126575"},"PeriodicalIF":0.0,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142815441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}